Acute demyelinating polyneuropathy induced by nivolumab

J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):435-437. doi: 10.1136/jnnp-2017-316510. Epub 2017 Aug 26.

Authors

Yuta Fukumoto¹, Motoi Kuwahara¹, Shigeru Kawai¹, Kenji Nakahama², Susumu Kusunoki¹

Affiliations

¹ Department of Neurology, Kindai University Faculty of Medicine, Osaka, Japan.
² Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan.

PMID: 28844069
DOI: 10.1136/jnnp-2017-316510

No abstract available

Keywords: clinical neurology; guillain-barre syndrome; neuroimmunology; neuropathy.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acute Disease
Aged
Antineoplastic Agents, Immunological / adverse effects*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Demyelinating Diseases / chemically induced*
Demyelinating Diseases / diagnosis
Demyelinating Diseases / physiopathology
Demyelinating Diseases / therapy
Diagnosis, Differential
Guillain-Barre Syndrome / diagnosis
Humans
Immunoglobulins, Intravenous / therapeutic use
Immunologic Factors / therapeutic use
Lung Neoplasms / drug therapy*
Male
Neural Conduction
Nivolumab / adverse effects*
Polyneuropathies / chemically induced*
Polyneuropathies / diagnosis
Polyneuropathies / physiopathology
Polyneuropathies / therapy

Substances

Antineoplastic Agents, Immunological
Immunoglobulins, Intravenous
Immunologic Factors
Nivolumab